Status:
WITHDRAWN
Cannabidiol Usage as an Adjunct Therapy for Crohn's Disease
Lead Sponsor:
University of Illinois at Chicago
Conditions:
Crohn Disease
Inflammatory Bowel Diseases
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
To date, few studies have assessed the efficacy and safety of Cannabinoids, compounds derived from the Cannabis plant, in patients with Crohn's disease. Our study seeks to pilot a randomized, placebo-...
Detailed Description
Crohn's disease is a type of inflammatory disease which can affect any portion of the gastrointestinal tract, from the mouth to the perianal area. Symptoms depend on location of the disease, however, ...
Eligibility Criteria
Inclusion
- Age 18 or older
- English-speaking
- Ileal and/or ileocolonic involvement as demonstrated by most recent endoscopy
- Short CDAI score \>150
- Have not received oral or intravenous steroids for \>1 month, or with stable dose for \>1 month if currently taking
- Stable dose of AZA for \>1 month, if currently taking
- Stable dose of anti-TNF inhibitor for \>1 month, if currently taking
Exclusion
- Pregnant or intend to become pregnant in the next 6 months
- Major abdominal surgery within the past 3 months
Key Trial Info
Start Date :
July 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2019
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT03467620
Start Date
July 1 2018
End Date
July 1 2019
Last Update
March 25 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.